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Background: First identiﬁed in 2012, Middle East respiratory
syndrome (MERS) is caused by an emerging human coronavirus,
which is distinct from SARS-CoV, and represents a novel member
of lineage C betacoronoviruses. Since its identiﬁcation, MERS-CoV
has been linked to over 964 infections manifesting with severe
morbidity and often mortality (i.e. approximately 400+ deaths) in
the Arabian Peninsula, Europe, in the US and in Korea. Human-
to-human transmission has been documented with nosocomial
transmission appearing to be an important route of infection. The
signiﬁcant recent increase in cases ofMERS in theMiddle East, cou-
pledwith the lack of effective antiviral therapies or vaccines to treat
or prevent this infection are signiﬁcant causes for concern.
Methods & Materials: A synthetic DNA plasmid based vac-
cine containing a full-length consensus MERS-S protein sequence
was constructed and the cellular and humoral immunogenicity
of MERS-vaccine was evaluated in mice, macaues, and camels.
Following immunization, NHPs were challenged with infectious
MERS-CoV (EMC/2012) andmonitored for signs of infection by clin-
ical scoring and examinations. Viral loadwasmeasured by qRT-PCR
and tissue sections were stained with H&E.
Results: An optimized DNA vaccine encoding the MERS spike
protein induced potent cellular immunity and antigen speciﬁc neu-
tralizing antibodies in mice, macaques and camels. Vaccinated
rhesus macaque monkeys seroconverted rapidly and exhibited
high levels of virus-neutralizing activity. Upon MERS viral chal-
lenge all of themonkeys in the control-vaccinated group developed
characteristic disease, including pneumonia. Vaccinated macaques
were protected and failed to demonstrate any clinical or radio-
graphic signs of pneumonia.
Conclusion: A consensus DNA MERS-vaccine was able to gen-
erate both a strong T cell and neutralizing antibody response in
multiple animalmodels, including camels, a natural host forMERS-
CoV and a probable source of human infection. MERS-vaccine was
also able to protect NHPs from an infectious MERS-CoV challenge.
These results demonstrate the promise of this consensus DNA
MERS-vaccine as a candidate for vaccine modality against this
emerging pathogen.
http://dx.doi.org/10.1016/j.ijid.2016.02.083
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Background: The objective of this research is to predict dis-
ease scenarios based on environmental conditions change and
climatic variability by combining regional climate models with
mathematicalmodels for disease transmission.Malaria anddengue
fever are the most important vector borne diseases in the trop-
ical and sub-tropicalcountries. Integration of large repositories
of geospatial and health data derived from traditional stream as
vital statistics, surveillanceandhospitalization, andnon-traditional
sources including social media networks provide valuable
insights into the spatio-temporal determinants of health and
wellbeing.
Methods & Materials: Data on infectious affected by vector
borne diseases (Malaria) are collected from various private and
public health centres, for the period starting January 1998 to
December 2013 in Tamil Nadu, India. Daily weather data is col-
lected from Regional Meteorological Centre, Chennai (Figure 1).
The suggested approach is implemented as a Big Data system using
lambda architecture and MapReduce data processing model (Fig-
ure 2). Pearson correlation coefﬁcient is computed in the proposed
framework to ﬁnd the climatic factors that greatly inﬂuence the
transmission of the vector borne diseases.
Results: This paper proposes a new architecture for modeling
the climate change and vector borne diseases in real-time. A variety
of big data analytical algorithms and data visualization approaches
were used in the proposed big data based disease surveillance
system to present the geographic regions at risk during this cen-
tury.We found thatmaximum temperature is positively correlated
while incidences of malaria and minimum temperature, wind,
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rainfall, humidity are negatively correlated with malaria incidence
(Figure 3).
Conclusion: The proposed early warning system is devel-
oped for continuous monitoring of information related to climatic
change and public health as they unfold. These systems are in
most instances, timely surveillance systems that collect informa-
tion on epidemic prone diseases in order to trigger prompt public
health interventions. Developing countries like India needs effec-
tive surveillance system and equity in health delivery programs for
takingcorrectiveactions to improvehealthconditionsof vulnerable
populations.
http://dx.doi.org/10.1016/j.ijid.2016.02.084
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Abstract: Malaria has always exerted a heavy toll on mankind.
At the turn of the 20th century millions died each year in India
alone. No other infectious disease has had more impact on the
human genome, particularly in tropical regions. In the past 150
years malaria has been ﬁrst controlled and then eliminated in
Europe, North America and Russia. This was achieved mainly by
a dual attack on the malaria vector –the anopheline mosquito, and
the malaria parasite in the human host. The successes in tem-
perate regions led to a global eradication effort endorsed by the
World Health Assembly in 1955. The campaign was armed with an
effective insecticide, DDT, and an excellent new antimalarial drug,
chloroquine. However by 1969 itwas acknowledged that the ambi-
tious goal of global eradication could not be achieved. Over the
next three decades many of the successes of the eradication effort
were reversed and malaria resurged across the tropical world. The
resurgence was associated with resistance to the available insecti-
cides and to the available antimalarial drugs. The tide has turned
again over the past 15 years with substantial increases in interna-
tional support for malaria control activities, widescale deployment
of insecticide treated mosquito nets, and the belated introduction
of highly effective artemisinin combination treatments for uncom-
plicated malaria and artesunate for severe malaria. Global malaria
mortality and morbidity have fallen substantially. Malaria eradi-
cation is now back on the agenda. The challenges now are how
to maintain the political and ﬁnancial support for malaria control
and elimination as case numbers fall, to reach those areas where
control activities are still weak, to address seriously control of P.
vivax, and to overcome two looming familiar threats; insecticide
and drug resistance. Resistance to pyrethroids is increasing and
resistance to artemisinin in P. falciparumhas emerged in South-East
Asia, andnowextends to the border of India. Artemisinin resistance
has not been contained, and combination partner drug resistance
has predictably followed. Spread of resistance to Africa would be
disastrous. A moderately effective vaccine has been developed and
new drugs are in the pipeline, but they will not generally available
for years. The future is uncertain.
http://dx.doi.org/10.1016/j.ijid.2016.02.085
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Abstract: Flaviviruses are some of the most important causes of
encephalitis, and other neurological syndromes globally, and have
an ability to spread to new areas causing large outbreaks.
Some are zoonotic, transmitted from animals to humans via
mosquitoes (e.g. Japanese encephalitis virus – JEV, and West Nile
virus – WNV) or ticks, (Tick-borne encephalitis virus – TBEV). For
other ﬂaviviruses humans are the natural hosts; these include
dengue virus (DENV), and Zika virus (ZIKV).
The clinical epidemiology of neurological disease caused by ﬂa-
viviruses varies. JEV is numerically the most important cause of
encephalitis with up to 70,000 cases annually across Asia. Almost
all those living in rural Asia become infected during childhood,
but only a small proportion develops neurological disease. Clinical
features include a non-speciﬁc febrile illness, aseptic meningitis,
febrile seizures, encephalitis, with Parkinsonian movement disor-
ders, and myelitis, causing a poliomyelitis-like ﬂaccid paralysis.
There is no speciﬁc treatment, but good supportive care is essen-
tial. Recognition and control of JE has been improved in recent years
throughbetter surveillance, improveddiagnostics, ondisability and
disease burden and greater use of vaccines.
Being a mosquito-borne zoonotic Flavivirus, WNV is broadly
similar to JEV. Its arrival and spread across the Americas in the last
15 years has taught us a great deal about the emergence of such
viruses among populations of animals and humans that have not
been exposed previously: disease tends to be seen in the elderly
and sick.
TBEV is seen in cooler parts of Asia and Europe where ticks pre-
dominate. Humans tend to become exposed to infected ticks in
wooded areas through tourism or work. The disease is well con-
trolled in countries with strong vaccination programmes.
For dengue and Zika virus humans are the natural hosts, and so
mostpatientspresentwith a febrile syndrome,whichmay includea
rash. However the neurological manifestations of dengue, includ-
ing encephalitis, have been recognised increasingly over the last
twenty years. The neurological associations of Zika virus infection
are beginning to be recognised with the ongoing large outbreaks in
South America.
http://dx.doi.org/10.1016/j.ijid.2016.02.086
